MINIMAL RESIDUAL DISEASE
Clinical trials for MINIMAL RESIDUAL DISEASE explained in plain language.
Never miss a new study
Get alerted when new MINIMAL RESIDUAL DISEASE trials appear
Sign up with your email to follow new studies for MINIMAL RESIDUAL DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Radiation-Chemo cocktail aims to boost stem cell transplant success in tough leukemias
Disease control TerminatedThis phase 1 trial is testing a combination of total marrow and lymphoid irradiation (TMLI) plus two chemotherapy drugs, fludarabine and melphalan, given before a donor stem cell transplant. The goal is to find the safest dose of radiation that can kill cancer cells while prepari…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 02, 2026 01:00 UTC
-
Engineered immune cells take aim at tough childhood leukemia
Disease control OngoingThis trial investigates a new type of immunotherapy called CAR T-cell therapy that targets two proteins, CD19 and CD22, found on B-cell leukemia cells. The therapy is given along with chemotherapy to children and young adults whose leukemia has come back or has not responded to s…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Immunotherapy boost may wipe out stubborn leukemia cells
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard tyrosine kinase inhibitors (TKIs) can eliminate tiny amounts of leftover leukemia cells in people with chronic myeloid leukemia (CML). About 40 adults with CML who still have detectable cancer marker…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New transplant method aims to reduce dangerous immune reactions
Disease control OngoingThis study tests a stem cell transplant method for people with blood cancers like leukemia or lymphoma. The approach uses chemotherapy, total body radiation, and a drug called cyclophosphamide after the transplant to prevent graft-versus-host disease, where donor cells attack the…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Engineered immune cells take on tough blood cancers in early trial
Disease control OngoingThis early-stage study tests a treatment that uses a patient's own immune cells, modified to recognize and attack cancer cells, for adults with B-cell blood cancers that have returned or not responded to standard therapy. The treatment is given with chemotherapy and sometimes an …
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Engineered immune cells take aim at stubborn blood cancers
Disease control OngoingThis early-phase trial tests a new type of immunotherapy for patients with acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN) that has returned or not responded to treatment. Researchers take a patient's own (or a donor's) T-cells, modify them in…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 26, 2026 17:52 UTC